Piper Sandler began coverage on shares of Regeneron Pharmaceuticals (NASDAQ:REGN – Free Report) in a research report report published on Tuesday morning, MarketBeat.com reports. The firm issued an overweight rating and a $875.00 target price on the biopharmaceutical company’s stock.
A number of other research analysts have also recently commented on REGN. Zacks Research cut Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Friday, February 6th. Evercore boosted their price objective on Regeneron Pharmaceuticals from $750.00 to $875.00 and gave the stock an “outperform” rating in a research report on Thursday, January 22nd. Wells Fargo & Company increased their target price on Regeneron Pharmaceuticals from $745.00 to $800.00 and gave the company an “equal weight” rating in a research report on Monday, February 2nd. Cantor Fitzgerald lifted their price target on Regeneron Pharmaceuticals from $740.00 to $800.00 and gave the company an “overweight” rating in a research note on Monday, February 2nd. Finally, Morgan Stanley boosted their price target on Regeneron Pharmaceuticals from $768.00 to $769.00 and gave the stock an “equal weight” rating in a report on Monday, February 2nd. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and nine have issued a Hold rating to the company. Based on data from MarketBeat, Regeneron Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $804.70.
Get Our Latest Research Report on Regeneron Pharmaceuticals
Regeneron Pharmaceuticals Trading Up 3.1%
Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) last released its quarterly earnings data on Friday, January 30th. The biopharmaceutical company reported $11.44 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $10.74 by $0.70. Regeneron Pharmaceuticals had a net margin of 31.41% and a return on equity of 13.04%. The business had revenue of $3.88 billion during the quarter, compared to analysts’ expectations of $3.76 billion. During the same period in the prior year, the company earned $12.07 EPS. The firm’s quarterly revenue was up 2.5% compared to the same quarter last year. Equities research analysts predict that Regeneron Pharmaceuticals will post 35.92 earnings per share for the current fiscal year.
Regeneron Pharmaceuticals Increases Dividend
The business also recently disclosed a quarterly dividend, which was paid on Thursday, March 5th. Stockholders of record on Friday, February 20th were given a dividend of $0.94 per share. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.5%. This is a positive change from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. The ex-dividend date was Friday, February 20th. Regeneron Pharmaceuticals’s dividend payout ratio is 9.05%.
Insider Buying and Selling
In other news, Director Huda Y. Zoghbi sold 1,638 shares of the business’s stock in a transaction that occurred on Thursday, February 19th. The shares were sold at an average price of $781.33, for a total value of $1,279,818.54. Following the transaction, the director owned 1,703 shares in the company, valued at approximately $1,330,604.99. The trade was a 49.03% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Bonnie L. Bassler sold 1,500 shares of the company’s stock in a transaction on Wednesday, January 7th. The shares were sold at an average price of $800.00, for a total transaction of $1,200,000.00. Following the completion of the sale, the director directly owned 1,703 shares in the company, valued at approximately $1,362,400. This represents a 46.83% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 5,274 shares of company stock valued at $4,142,738 in the last ninety days. Insiders own 7.02% of the company’s stock.
Hedge Funds Weigh In On Regeneron Pharmaceuticals
Several hedge funds and other institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. raised its position in shares of Regeneron Pharmaceuticals by 0.3% in the 4th quarter. Vanguard Group Inc. now owns 9,075,153 shares of the biopharmaceutical company’s stock worth $7,004,838,000 after acquiring an additional 26,884 shares in the last quarter. State Street Corp boosted its position in shares of Regeneron Pharmaceuticals by 0.9% during the 2nd quarter. State Street Corp now owns 4,832,002 shares of the biopharmaceutical company’s stock valued at $2,536,801,000 after purchasing an additional 42,343 shares in the last quarter. Dodge & Cox grew its stake in Regeneron Pharmaceuticals by 1.0% during the fourth quarter. Dodge & Cox now owns 4,596,358 shares of the biopharmaceutical company’s stock worth $3,547,791,000 after purchasing an additional 45,513 shares during the period. Franklin Resources Inc. grew its stake in Regeneron Pharmaceuticals by 4.4% during the fourth quarter. Franklin Resources Inc. now owns 2,560,004 shares of the biopharmaceutical company’s stock worth $1,975,990,000 after purchasing an additional 106,861 shares during the period. Finally, Nuveen LLC increased its holdings in Regeneron Pharmaceuticals by 71.1% in the fourth quarter. Nuveen LLC now owns 2,010,517 shares of the biopharmaceutical company’s stock worth $1,551,858,000 after purchasing an additional 835,240 shares in the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.
Regeneron Pharmaceuticals News Summary
Here are the key news stories impacting Regeneron Pharmaceuticals this week:
- Positive Sentiment: Japan approved Dupixent for moderate-to-severe bullous pemphigoid, giving Regeneron (co‑developer of Dupixent) a first targeted approval in a rare skin disease — this expands Dupixent’s labeled indications and potential revenue streams. A Look At Regeneron Pharmaceuticals (REGN) Valuation After Japan’s Approval Of Dupixent For Bullous Pemphigoid
- Positive Sentiment: Piper Sandler initiated coverage with an “overweight” and a $875 price target, signaling institutional bullishness and providing a high-profile positive catalyst for investor sentiment. Regeneron now covered by Piper Sandler
- Positive Sentiment: Broker note coverage and buy-side interest (Seeking Alpha summary of Piper’s overweight) reinforce the upgrade momentum and may drive incremental flows into the stock. Regeneron a new overweight at Piper on Dupixent, pipeline
- Positive Sentiment: Jim Cramer mentioned Regeneron as a notable GLP‑1/weight-loss play, which often fuels retail buying and short‑term volume uplift. Regeneron Pharma (REGN) Shares Up After Jim Cramer Called It a Good Stock
- Positive Sentiment: Regeneron and partner Bayer’s high‑dose aflibercept Phase 3 program in China is approaching a key readout/inflection point for eye‑care growth — a positive potential revenue driver if results support label expansion. High-Dose Aflibercept Trial in China Nears Key Inflection Point
- Neutral Sentiment: Truist lowered its price target slightly (from $818 to $801) but kept a “buy” rating — modestly reduces upside from that shop but leaves institutional endorsement intact. Truist lowers REGN price target
- Neutral Sentiment: Long-form bullish coverage (The Motley Fool) highlights Regeneron’s strengths and long‑term potential but is more thematic and less likely to move the stock near‑term than concrete approvals or readouts. Regeneron: A Strong Contender in the Biotech Arena
- Neutral Sentiment: Broader industry headlines (Bayer Kerendia EU approval, Merck cholesterol data, AstraZeneca COPD wins) illustrate an active competitive/innovation environment; these are worth monitoring but not direct Regeneron-specific negatives today. Bayer Wins EC Approval to Expand Kerendia
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.
Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.
See Also
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
